HPLC-UV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-11. Numbers and descriptions here follow the published literature rather than marketing material.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
=== Hunger === Because patients are being fed intravenously, the subject does not physically eat, resulting in intense hunger pangs (pains). The brain uses signals from the mouth (taste and smell), the stomach and gastrointestinal tract (fullness) and blood (nutrient levels) to determine conscious feelings of hunger. In cases of TPN, the taste, smell and physical fullness requirements are not met, and so the patient experiences hunger, although the body is being fully nourished. Patients who eat food despite the inability can experience a wide range of complications, such as refeeding syndrome.
In children, orthodontic treatment to expand the volume of the nasal airway, such as nonsurgical rapid palatal expansion is common. The procedure has been found to significantly decrease the AHI and lead to long-term resolution of clinical symptoms. Since the palatal suture is fused in adults, regular RPE using tooth-borne expanders cannot be performed. Mini-implant assisted rapid palatal expansion (MARPE) has been recently developed as a non-surgical option for the transverse expansion of the maxilla in adults. This method increases the volume of the nasal cavity and nasopharynx, leading to increased airflow and reduced respiratory arousals during sleep. Changes are permanent with minimal complications.
The lungs are part of the lower respiratory tract, and accommodate the bronchial airways when they branch from the trachea. The bronchial airways terminate in alveoli which make up the functional tissue (parenchyma) of the lung, and veins, arteries, nerves, and lymphatic vessels. The trachea and bronchi have plexuses of lymph capillaries in their mucosa and submucosa. The smaller bronchi have a single layer of lymph capillaries, and they are absent in the alveoli. The lungs are supplied with the largest lymphatic drainage system of any other organ in the body. Each lung is surrounded by a serous membrane of visceral pleura, which has an underlying layer of loose connective tissue attached to the substance of the lung.
Glycolysis and glycogenolysis defects: McArdle's disease, phosphofructokinase deficiency, glycogen storage diseases VIII, IX, X and XI Lipid metabolism defects: carnitine palmitoyltransferase I and II deficiency, deficiency of subtypes of acyl CoA dehydrogenase (LCAD, SCAD, MCAD, VLCAD, 3-hydroxyacyl-coenzyme A dehydrogenase deficiency), thiolase deficiency Mitochondrial myopathies: deficiency of succinate dehydrogenase, cytochrome c oxidase and coenzyme Q10 Others: glucose-6-phosphate dehydrogenase deficiency, myoadenylate deaminase deficiency and muscular dystrophies
Lord Robert Cecil on 2 December 1917, assured an audience that the government fully intended that "Judea [was] for the Jews." Yair Auron opines that Cecil, then a deputy Foreign Secretary representing the British Government at a celebratory gathering of the English Zionist Federation, "possibly went beyond his official brief" in saying (he cites Stein) "Our wish is that Arabian countries shall be for the Arabs, Armenia for the Armenians and Judaea for the Jews". The following October Neville Chamberlain, while chairing a Zionist meeting, discussed a "new Jewish State." At the time, Chamberlain was a Member of Parliament for Ladywood, Birmingham; recalling the event in 1939, just after Chamberlain had approved the 1939 White Paper, the Jewish Telegraph Agency noted that the Prime Minister had "experienced a pronounced change of mind in the 21 years intervening" A year later, on the Declaration's second anniversary, General Jan Smuts said that Britain "would redeem her pledge ... and a great Jewish state would ultimately rise." In similar vein, Churchill a few months later stated:
Sources: en.wikipedia.org
Cystathionine is an intermediate in the synthesis of cysteine from homocysteine. It is produced by the transsulfuration pathway and is converted into cysteine by cystathionine gamma-lyase (CTH). Biosynthetically, cystathionine is generated from homocysteine and serine by cystathionine beta synthase (upper reaction in the diagram below). It is then cleaved into cysteine and α-ketobutyrate by cystathionine gamma-lyase (lower reaction). An excess of cystathionine in the urine is called cystathioninuria.
During the trial of alleged 9/11 conspirator Zacarias Moussaoui, the U.S. government identified five people as having been completely aware of the operation's details; bin Laden, Mohammed, Mohammed Atef, Abu Turab al-Urduni, and bin al-Shibh. The attacks were conceived by Khalid Sheikh Mohammed, who first presented it to bin Laden in 1996. Many targets were listed that al-Qaeda hijackers could crash planes into, including the Library Tower (now the U.S. Bank Tower) in Los Angeles. Bin Laden rejected the plan for being too elaborate. Al-Qaeda's first attacks against the U.S. after Bin Laden's 1998 fatwa were the 1998 African embassy bombings. In late 1998 or early 1999, bin Laden approved Mohammed to go forward with a new version of the 1996 plan. Bin Laden provided leadership and financial support, and was involved in selecting participants. Atef provided operational support, including target selections and helping arrange travel for the hijackers. He initially selected Nawaf al-Hazmi and Khalid al-Mihdhar, both experienced jihadists who had fought in the Bosnian war. The two arrived in the United States in mid-January 2000. In early 2000, they took flying lessons in San Diego, California. Both spoke little English. They performed poorly in flying lessons, and so they eventually served as secondary "muscle" hijackers. The Hamburg cell in Germany included Islamists who were key operatives in the 9/11 attacks. In late 1999, cell members bin al-Shibh, Mohamed Atta, Marwan al-Shehhi, and Ziad Jarrah arrived to meet al-Qaeda in Afghanistan.
=== Additional references === Salzer, A. (1999). "Nomenclature of Organometallic Compounds of the Transition Elements". Pure Appl. Chem. 71 (8): 1557–1585. doi:10.1351/pac199971081557. S2CID 14367196. Crabtree, Robert H. (2005). The Organometallic Chemistry of the Transition Metals (4th ed.). Wiley-Interscience.ISBN 0470257628 Miessler, Gary L.; Tarr, Donald A. (2004). Inorganic Chemistry. Upper Saddle River, NJ: Pearson Education. ISBN 978-0-13-035471-6. Cotton, F. A.; Wilkinson, G. (1988). Inorganic Chemistry (5th ed.). Wiley. pp. 626–7. Togni, A.; Halterman, R. L. (1998). Metallocenes. Wiley-VCH.
== Second island chain == The second island chain, also called the "second island cloud" by Earl Hancock Ellis, has two different interpretations, but the version most commonly used refers to the island chain which is formed by Japan's Bonin Islands and Volcano Islands, in addition to the Mariana Islands (most notably Guam, an unincorporated American overseas territory with a heavily fortified military base), western Caroline Islands (Yap and Palau), and extends to Western New Guinea. The chain serves as the eastern maritime boundary of the Philippine Sea. As it is located within the middle portion of the West Pacific, it acts as a second strategic defense line for the United States.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.